Quick Answer
Apogee Therapeutics, Inc. reported Net Income of -$255.84 million for fiscal year 2025.
Apogee Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net Income | -$255.84M -40.5% |
-$182.15M -116.9% |
-$83.98M -111.1% |
-$39.78M |
| Diluted EPS | -$4.22 -27.9% |
-$3.30 +1.8% |
-$3.36 +79.2% |
-$16.16 |
| Total Assets | $937.13M +24.3% |
$753.95M +87.8% |
$401.40M +164.0% |
$152.06M |
| Cash and Equivalents | $131.55M -7.2% |
$141.79M +19.8% |
$118.32M -22.1% |
$151.89M |
| R&D Expense | $214.71M +27.9% |
$167.87M +145.3% |
$68.42M +146.3% |
$27.79M |
| Operating Income | -$285.60M -31.7% |
-$216.87M -133.2% |
-$93.00M -202.7% |
-$30.73M |
| Shares Outstanding | 68.40M +17.8% |
58.06M +20.1% |
48.34M | 0 |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$65.02M | -32.6% | +1.6% |
| Diluted EPS | September 30, 2025 | -$1.11 | -29.1% | +1.8% |
| Total Assets | September 30, 2025 | $626.16M | -19.3% | -4.8% |
| Cash and Equivalents | September 30, 2025 | $107.91M | -9.1% | -13.1% |
| R&D Expense | September 30, 2025 | $54.18M | +18.5% | -2.7% |
| Operating Income | September 30, 2025 | -$71.28M | -21.5% | +2.6% |
| Shares Outstanding | September 30, 2025 | 59.32M | +4.2% | +1.3% |
- Apogee Therapeutics, Inc. reported Net Income of -$255.84 million for fiscal year 2025.
- Apogee Therapeutics, Inc. showed a decrease of -40.5% in Net Income compared to the prior fiscal year.
- Apogee Therapeutics, Inc. reported Diluted EPS of $4.22 per share (loss) for fiscal year 2025.
- Apogee Therapeutics, Inc. showed a decrease of -27.9% in Diluted EPS compared to the prior fiscal year.
- Apogee Therapeutics, Inc. reported Total Assets of $937.13 million for fiscal year 2025.
- Apogee Therapeutics, Inc. showed an increase of +24.3% in Total Assets compared to the prior fiscal year.
- Apogee Therapeutics, Inc. reported Cash and Equivalents of $131.55 million for fiscal year 2025.
- Apogee Therapeutics, Inc. showed a decrease of -7.2% in Cash and Equivalents compared to the prior fiscal year.
- Apogee Therapeutics, Inc. reported R&D Expense of $214.71 million for fiscal year 2025.
- Apogee Therapeutics, Inc. showed an increase of +27.9% in R&D Expense compared to the prior fiscal year.
- Apogee Therapeutics, Inc. reported Operating Income of -$285.60 million for fiscal year 2025.
- Apogee Therapeutics, Inc. showed a decrease of -31.7% in Operating Income compared to the prior fiscal year.
- Apogee Therapeutics, Inc. reported Shares Outstanding of 68.40 million shares for fiscal year 2025.
- Apogee Therapeutics, Inc. showed an increase of +17.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: